Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biogen Idec Agrees To Buy Syntonix

This article was originally published in The Pink Sheet Daily

Executive Summary

Biogen gains preclinical hemophilia B agent and novel delivery technology that could allow less frequent dosing.

You may also be interested in...



Hemophilia In Transition: Can Next-Gen Products Wake A Sleepy Market?

The hemophilia market could be about to undergo a wave of innovation not seen since the introduction of recombinant factor 20 years ago in response to a crisis in contaminated plasma products. Over the next three years, long-acting factor products may have an even more transformative effect on the market, reshuffling segment shares, moving patients to prophylactic use, and expanding an already substantial global market. But will the improvements be enough to sway providers and payors?

Biogen Reports Progress In Late-Stage Programs, Plus Some Bumps In The Road

Biogen Idec reported steady progress in the clinic for four late-stage programs, including hemophilia. Recent bumps include a three-month delay for the MS product BG-12, but nothing that would derail its Phase III pipeline.

Biogen Idec Business Development Plan Includes Small Molecules For Oncology

The company expects the bulk of expenditures from a $200 mil. business development plan will go toward up-front milestones and new clinical costs for in-licensed drugs.

Topics

UsernamePublicRestriction

Register

LL1135866

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel